Biocept Aandeel

Biocept EV/FCF

Delisted

De EV/VKS (Ondernemingswaarde op vrije kasstroom) van Biocept (BIOC) per 11 aug 2026 bedraagt 0,40. In het voorgaande jaar bedroeg EV/VKS (Ondernemingswaarde op vrije kasstroom) -10,19 — een verandering van -103,97% (hoger).

EV/FCF

0,40

YoY

-103,97%

Laatst bijgewerkt:

EV/VKS (Ondernemingswaarde op vrije kasstroom) van Biocept is 2026 0,40 . EV/VKS (Ondernemingswaarde op vrije kasstroom) van Biocept was 2025 -10,19 . Het is daarmee -103,97% hoger lager dan het jaar ervoor.
Access this data via the Eulerpool API

Biocept Aandelenanalyse

Wat doet Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel Biocept

EV/VKS (Ondernemingswaarde op vrije kasstroom) van Biocept bedraagt 0,40 in 2026.

EV/VKS (Ondernemingswaarde op vrije kasstroom) van Biocept is veranderd van -10,19 naar 0,40, wat een verandering van -103,97% vertegenwoordigt. De waarde is hoger dan het vorige jaar.

Op Eulerpool vindt u de volledige historische ontwikkeling van EV/VKS (Ondernemingswaarde op vrije kasstroom) Biocept sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

De EV/VKS-ratio meet de ondernemingswaarde ten opzichte van de vrije kasstroom en geeft een beeld van het werkelijke kasgenererend vermogen van een bedrijf.

Om van EV/VKS (Ondernemingswaarde op vrije kasstroom) te evalueren, is het essentieel dit te vergelijken met andere bedrijven in dezelfde sector. Op Eulerpool kunt u maatstaven direct vergelijken.

Een 'goede' varieert per branche en bedrijfsfase. Op Eulerpool kunt u maatstaven direct vergelijken.

Access this data via the Eulerpool API

Waardering — Biocept

Alle kengetallen — Biocept